-
Comparative efficacy and safety of the trastuzumab biosimilar HLX02 versus originator trastuzumab in the neoadjuvant THP-EC regimen for early-stage HER2-positive breast cancer: a real-world stud
Author: Wang, Mingyu; Sheng, Xingye; Zhu, Qiannan; Shen, Danni; Li, Junhan; Tao, Xincheng; Wang, Jue; Zha, Xiaoming
Journal: EXPERT OPINION ON BIOLOGICAL THERAPY. 2026; Vol. 26, Issue 3, pp. 355-362. DOI: 10.1080/14712598.2026.2649512
-
Clinical outcomes of long-term infliximab treatment for 15 years in patients with Crohn's disease: a retrospective stud
Author: Chen, Zihan; Chen, Mengqi; Huang, Jieqing; Liu, Linxin; Li, Tong; Zeng, Zhirong; Zhuang, Xiaojun
Journal: EXPERT OPINION ON BIOLOGICAL THERAPY. 2026; Vol. 26, Issue 2, pp. 199-211. DOI: 10.1080/14712598.2026.2635521
-
The potential role of biosimilars in healthcare sustainability in Latin Americ
Author: Schaffel, Rony; Cornes, Paul; Espinoza, Manuel A.; Gomez-Almaguer, David; Maiolino, Angelo; Freire, Daniel; Foierl, Tobias
Journal: EXPERT OPINION ON BIOLOGICAL THERAPY. 2025; Vol. 25, Issue 6, pp. 633-647. DOI: 10.1080/14712598.2025.2507173
-
The potential of factor XII inhibitors in preventing hereditary angioedema attack
Author: Hooi, James K. Y.; Wong, Jane C. Y.; Li, Philip H
Journal: EXPERT OPINION ON BIOLOGICAL THERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14712598.2025.2512128
-
Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesi
Author: Zhang, Yan; Liu, Xinyu; Ren, Shengxiang
Journal: EXPERT OPINION ON BIOLOGICAL THERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14712598.2025.2487512
-
An up-to-date review of emerging biologic therapies for hypercholesterolemi
Author: Tomlinson, Brian
Journal: EXPERT OPINION ON BIOLOGICAL THERAPY. 2025; Vol. 25, Issue 1, pp. 69-78. DOI: 10.1080/14712598.2024.2442455
